Table 1. Characteristics of evaluation panel.
| Characteristics | Recent infections (n = 44) | Long-term infections (n = 117) | “Challenge specimens” (n = 19) | ||||||
| Subtype B | Subtype „non-B“ | Subtype B | Subtype „non-B“ | ARV-treated | Slow progressors | ||||
| Number of specimen | 25 | 19 | 101 | 16 | 14 | 5 | |||
| Age | Median (IQR) | 33 (29–39) | 40 (31–47) | 34 (30–39) | 36 (27–44) | 35 (26–39) | 32 (24–33) | ||
| Sex | Male | 25 (100%) | 12 (63%) | 100 (99%) | 9 (56%) | 14 (100%) | 5 (100%) | ||
| Female | - | 7 (37%) | 1 (1%) | 7 (44%) | - | - | |||
| Category of SC | Acute SC | 25 (100%) | 18 (95%) | 100 (99%) | 14 (88%) | 8 (57%) | 2 (40%) | ||
| Documented SC | 0 | 1 (5%) | 1 (1%) | 2 (12%) | 6 (34%) | 3 (60%) | |||
| Duration of infection (IQR) | 62 d (42–89) | 35 d (28–54) | 122 wk (83–168) | 100 wk (65–179) | 308 wk (149–400) | 447 wk (438–452) | |||
| Risk groups | MSM | 25 (100%) | 5 (26%) | 94 (93%) | 5 (31%) | 14 (100%) | 4 (80%) | ||
| Hetero | - | 10 (52%) | 3 (3%) | 10 (62%) | - | - | |||
| IDUs | - | 2 (11%) | 1 (1%) | 1 (6%) | - | - | |||
| Unknown/other | - | 2 (11%) | 3 (3%) | - | - | 1 (20%) | |||
| CD4 cell count | Cells/µl (IQR) | 561 (430–678) | 511 (276–787) | 409 (314–538) | 438 (268–567) | set 1 (n = 8): 484 (403–595) | 714 (601–967) | ||
| set 2 (n = 6): 261 (257–299) | |||||||||
| Subtype | B | A1,C,CRF01_AE, | B | A1,C,CRF01_AE, | B; 1x not analyzed | B | |||
| D,F1,CRF02_AG | D,G,CRF02_AG | ||||||||
IQR = Interquartile range, SC = seroconverter, d = days, wk = weeks.